Wingman blends were developed by Eybna Technologies Ltd. Eybna is a global leader in research and development of cannabis terpene-based solutions, with the mission of bringing the benefits of cannabis to more patients. By isolating the medicinal properties found in different strains, Eybna seeks to achieve cannabis-based medicine that is tailored to treat specific medical conditions.
The main trigger for Wingman’s development was the fact that more than 80% of patients in Israel mix their medical cannabis with addictive tobacco. Wingman was developed as a part of a 3 year study conducted by a team of chemists, herbal medicine and cannabis experts. The Wingman R&D process included a test group of approximately 250 medical patients with various medical conditions who assisted Eybna in creating the accurate herbal and terpene formulation to fit the market’s taste preferences.